主页 > 医学文档 >
【drug-news】新型抗哮喘药一期临床试验
BioWa, Inc. Begins Phase 1 Clinical Trial In Asthma
BioWa, Inc. announced today that it is beginning its Phase 1 clinical trial to evaluate the safety and tolerability of BIW-8405, BioWa's anti-IL-5 receptor monoclonal antibody (Mab). The Mab is being developed for the treatment of asthma.
"The commencement of the BIW-8405 clinical studies is a significant step for BioWa's technology platform, demonstrating our commitment to building a pipeline of Antibody-Dependent Cellular Cytotoxicity (ADCC) enhanced therapeutic products, positioning BioWa as a key player in asthma therapeutics," said Dr. Nobuo Hanai, President and CEO of BioWa, Inc. "We believe that ADCC enhancement of antibodies will overcome many existing problems of antibody therapeutics today. We are pursuing the discovery and development of high value proprietary therapeutic products through the use of POTELLIGENT(TM) Technology."
"Moving forward with our clinical program for BIW-8405 is an exciting step for BioWa, especially since this is the first Mab of the BioWa pipeline to enter human trials," said George L. Spitalny, Ph.D., BioWa's Senior Vice President of Research and Development.
About BIW-8405
The IL-5 receptor is expressed predominantly on the surface of a class of white blood cells known as eosinophils. These are one of several types of white blood cells that act to combat infection. However, in a more negative action, eosinophils have been implicated as the major cause of problems in the lung associated with various forms of asthma. BIW-8405 is being developed to reverse the debilitating effects of asthma by acting to eliminate eosinophils that accumulate locally in the lung.
About Asthma
The overall market for BIW-8405 could potentially gross over $500M worldwide peak sales. The number of patients affected by asthma is growing significantly. The asthma market is predicted to increase from the current $12B to over $19B worldwide by the year 2009.
About POTELLIGENT(TM) Technology
ADCC activity is an important function of the human immune system, whereby immune cells can kill target cells, e.g. cancer cells. Several anti-cancer therapeutic antibodies that are on the market today have ADCC activity as one of their mechanisms for the killing of tumor cells. Enhancement of this activity is one promising approach in the next generation of antibody technologies.
POTELLIGENT(TM) technology involves the reduction of the amount of fucose in the carbohydrate structure of an antibody using a proprietary fucosyltransferase-knockout CHO cell line as a production cell. Research shows that POTELLIGENT(TM) technology significantly enhances ADCC activity of an antibody in vitro, thereby increasing the potential for improved activity in vivo.
About BioWa, Inc.
BioWa is a wholly owned subsidiary of Kyowa Hakko Kogyo Co., Ltd., Japan's leading pharmaceutical and largest biotech company, and is the exclusive worldwide licensor of POTELLIGENT(TM) technology, which creates high ADCC monoclonal antibodies. Currently, BioWa is developing ADCC enhanced monoclonal antibody-based therapeutics to fight cancer and other life-threatening and debilitating diseases and both BioWa and Kyowa have POTELLIGENT(TM) antibody products in various clinical stages. BioWa creates and develops enhanced ADCC antibodies for itself and others, offering a full range of antibody discovery and development capabilities. For more information about BioWa, visit its web site at http://www.biowa.com. 该篇我已认领,如48小时内未交出译文,请战友们继续自由认领. BioWa, Inc. Begins Phase 1 Clinical Trial In Asthma
bioWa 公司着手进行治疗哮喘药物的1期临床研究
BioWa, Inc. announced today that it is beginning its Phase 1 clinical trial to evaluate the safety and tolerability of BIW-8405, BioWa's anti-IL-5 receptor monoclonal antibody (Mab). The Mab is being developed for the treatment of asthma.
bioWa 公司今天宣布，将进行BIW-8405 安全性和耐受性的1期临床研究，BIW-8405 是biowa公司研发的抗IL-5 受体的单克隆抗体(Mab)，这种单克隆受体用于治疗哮喘。
"The commencement of the BIW-8405 clinical studies is a significant step for BioWa's technology platform, demonstrating our commitment to building a pipeline of Antibody-Dependent Cellular Cytotoxicity (ADCC) enhanced therapeutic products, positioning BioWa as a key player in asthma therapeutics," said Dr. Nobuo Hanai, President and CEO of BioWa, Inc. "We believe that ADCC enhancement of antibodies will overcome many existing problems of antibody therapeutics today. We are pursuing the discovery and development of high value proprietary therapeutic products through the use of POTELLIGENT(TM) Technology."
“BIW-8405 临床试验的开始，对于BioWa's的技术平台而言具有显著的意义，这标志我们可以构建系列化的ADCC（抗体依赖性细胞毒性）强效产品，并且决定着Biowa公司成为治疗哮喘中关键的一员。”
阅读本文的人还阅读：
作者:admin@医学,生命科学 2011-06-22 05:12
医学,生命科学网